Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Canagliflozin For Type 1 Diabetes
2 dosages compared with placebo
Canagliflozin reduced HbA1c levels, body weight, and insulin dose, and did not increase hypoglycemia in a double-blind study involving 351 patients with type 1 diabetes inadequately controlled with insulin.
Participants were all taking insulin and their HbA1c ranged from 7% to 9%. They were randomized to receive canagliflozin 100 or 300 mg, or placebo.
Among the results at week 18:
• More patients had both HbA1c reduction ≥0.4% and no weight gain with canagliflozin vs placebo.
• Both treatment doses reduced HbA1c, weight, and insulin dose vs placebo.
• Hypoglycemia incidence was similar across groups; severe hypoglycemia rates were low.
• Overall incidence of adverse events was 55.6%, 67.5%, and 54.7% with canagliflozin 100 and 300 mg, and placebo, respectively.
• Diabetic ketoacidosis occurred in the treatment groups, but not in those taking placebo.
Citation: Henry R, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. [Published online ahead of print October 20, 2015]. Diabetes Care. doi:10.2337/dc15-1730.